Gilead Sciences Inc articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2015/07/28 04:19
2015/07/28 04:19
1m
In the stock market, growth managers and value managers often see themselves as warring camps. Value managers look for cheap stocks. Growth managers look for rapidly rising earnings. Yet many of the...
2015/07/28 04:19
2015/07/28 04:19
Latest videos
2015/07/27 17:22
2015/07/27 17:22
10h
GILD traded below its daily resistance level (quality: 73 days, meaning that the stock is crossing a resistance level set by the last 73 calendar days. The resistance price is defined by the Price -...
2015/07/27 17:22
2015/07/27 17:22
10h
Harvoni, along with Gilead's other hepatitis C treatment regiment Sovaldi, are two of Gilead's most profitable treatments and combined represented about 60% of the company's revenue, about $4.55...
2015/07/27 16:56
2015/07/27 16:56
10h
When we first exposed the shockingly dire lack of breadth in US equity markets, it was shrugged off by the mainstream media as yet another 'worry' in the wall to climb. It seems, however, that facts...
2015/07/25 21:38
2015/07/25 21:38
2d
An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options — all much more effective but...
2015/07/24 22:49
2015/07/24 22:49
3d
Shares in drug maker Biogen Inc. fell 22% on Friday, losing roughly $20 billion in market value, after the company reported a sharp slowdown in sales growth for its flagship multiple-sclerosis pill...
2015/07/24 22:27
2015/07/24 22:27
3d
French drugs firm Sanofi's logo is pictured inside the company's headquarters during the company's 2014 annual results presentation in Paris February 5, 2015. WASHINGTON The U.S. Food and Drug...
2015/07/24 22:21
2015/07/24 22:21
3d
TRENTON - An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options - all much more effective...
2015/07/24 15:10
2015/07/24 15:10
3d
ProNAi Therapeutics stock soars in first week as public companyPriced at $17, stock soared past $30 on opening dayCommentsEmailPrint ProNAI Therapeutics Inc. (Nasdaq: DNAI), a Michigan company that...
2015/07/24 07:17
2015/07/24 07:17
3d
Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Products, LP (Janssen ), has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to...
2015/07/23 10:17
2015/07/23 10:17
4d
VANCOUVER, Brits-Columbia--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) heeft vandaag uitgebreide 48 weken-gegevens bekendgemaakt van een open-label Fase 3-onderzoek (Studie 109) dat het...
2015/07/22 13:48
2015/07/22 13:48
5d
Established in 1998, the Health Care Select Sector SPDR Fund (XLV) is up 8.5% since its inception. Its portfolio includes companies from various health care industries including pharmaceuticals,...
2015/07/22 08:17
2015/07/22 08:17
5d
VANCOUVER, Columbia Britannica--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) ha comunicato oggi i dati dettagliati a 48 settimane derivati da uno studio in aperto di Fase 3 (Studio 109) inteso...
2015/07/21 21:17
2015/07/21 21:17
6d
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2015 financial results will be released on Tuesday, July 28, at 4:05 p.m. Eastern...
2015/07/21 19:43
2015/07/21 19:43
6d
A French teenager has been effectively cured of AIDS, showing no signs of active infection a dozen years after stopping treatment - a development that is helping spur the largest trial ever aimed at...
2015/07/21 18:17
2015/07/21 18:17
6d
VANCOUVER, British Columbia--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed 48-week data from an open-label Phase 3 study (Study 109) evaluating its investigational...
2015/07/15 17:50
2015/07/15 17:50
12d
Shares of Celgene and Receptos rose as much as 11 percent to record highs on Wednesday. Cowen & Co's Eric Schmidt said the deal could be a "steal" for Celgene, if Receptos' ozinamod proves...
2015/07/14 20:04
2015/07/14 20:04
13d
Johnson & Johnson's recovering U.S. consumer health business, following years of recalls that kept Tylenol, Motrin and other marque brands off store shelves, put a much-needed Band-Aid over a rough...
2015/07/10 19:51
2015/07/10 19:51
17d
Maker of Costly Drug Spent Heavily on Hospitality for Doctors Gilead Sciences Inc., the maker of the costly Sovaldi hepatitis C pill that has attracted congressional scrutiny, bought doctors about...
2015/07/04 15:18
2015/07/04 15:18
23d
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) kondigde vandaag aan dat het Japans Ministerie van Gezondheid, Arbeid en Welzijn (MHLW, Japanese Ministry of Health,...
2015/07/28 04:19
2015/07/28 04:19
Latest from Twitter